CJC-1295 DAC + Ipamorelin

Source-reported examples · not treatment recommendations

Amount

CJC: 1–2 mg per week; ipamorelin: 100–300 micrograms total per day

Frequency

CJC weekly; ipamorelin daily

Cycle / observation period

8–12 weeks; source also mentions 16 weeks

Route / research model

Subcutaneous

This is a two-vial stack, not a premixed blend. The source’s combination schedule is not independently validated here.

Titration & progression

A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.

Compare vial strengths here. A different vial size changes the available material, not the biological dose.

Diluent & formulation

Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.

Separate vials: 2 mg + 5 mg or 5 mg + 5 mg. Each ingredient needs its own material total and formulation instructions. These are not premixed products.

Read the reconstitution guide →

Selected observations from the cited research. Each finding retains its study population, formulation and limitations.

Studies of individual ingredients do not establish the effects of this finished combination. Combination studies are identified explicitly below.

• The long-acting CJC-1295 trial reported sustained GH and IGF-I responses in healthy adults. Its findings concern that component and preparation. They do not quantify the added effect of ipamorelin. ^[1]
• A 1999 study measured ipamorelin concentrations and GH responses after intravenous administration in healthy male volunteers. It characterized single-component pharmacology rather than the CJC-1295 pairing. ^[2]
• A 2001 adult-rat study examined ipamorelin in a glucocorticoid model. It reported improved maximum tetanic tension compared with glucocorticoid alone. Its described treatment groups did not include CJC-1295. ^[3]

Read the complete research profile →

No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.

Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.

Bibliography checked September 22, 2026: 26 entries mapped from 2 source pages. Medical and supporting references are retained below; supplier entries are excluded.

1. Original pharmacology study
2. Original human study
3. Original rat experiment
4. European Journal of EndocrinologyFurther reading · Listed in reference bibliography.
5. Endocrine ReviewsFurther reading · Listed in reference bibliography.
6. Sleep Medicine ReviewsFurther reading · Listed in reference bibliography.
7. Translational Andrology and Urology (PMC)Further reading · Listed in reference bibliography.
8. International Journal of Surgery (PubMed)Further reading · Listed in reference bibliography.
9. NCBI BookshelfFurther reading · Listed in reference bibliography.
10. CDCGeneral guidance · Listed in reference bibliography.
11. Growth Hormone & IGF Research (ScienceDirect)Further reading · Listed in reference bibliography.
12. Physiological ReviewsFurther reading · Listed in reference bibliography.
13. Clinical Drug Investigation (PMC)Further reading · Listed in reference bibliography.

Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.